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A B S T R A C T
Objectives: Dapagliflozin is an inhibitor of the human sodium-glucose co-transporter 2
(SGLT2) that has been shown to improve glycaemic control in patients with type 2 diabetes
mellitus (T2DM). This study aimed to evaluate the characteristics and treatment patterns of
dapagliflozin users in comparison to users of other anti-diabetic (AD) treatments in Ger-
many.
Methods: Data from patients with T2DM initiating at least one prescription for dapagliflozin
or other AD therapy between November 2012 and April 2014 were collected from the IMS
German Disease Analyzer database.
Results: The use of dapagliflozin combination therapy (n = 1034; 74%) was more common
than monotherapy (n = 371; 26%). In comparison with other AD therapy users, a higher per-
centage of dapagliflozin users were 664 years of age (62.3% vs. 36.4%), and a higher propor-
tion were male (59.1% vs. 53.6%). The average duration of diabetes was comparable
between dapagliflozin patients and other AD therapy users (5.7 years vs. 5.5 years), how-
ever higher levels of HbA1c were found in dapagliflozin users (8.2% (66 mmol/mol) vs.
7.5% (58 mmol/mol). For the vast majority (71.5% of 10 mg dapagliflozin users and 88.9%
of 5 mg users), dapagliflozin was prescribed in combination with other AD therapy.
Conclusions: Patients starting on dapagliflozin differed in several demographic and health-
related respects to patients starting another AD therapy during the same period. Dapagli-
flozin was predominantly used as a component of combination therapy, adding on to exist-
ing therapy. After initiation, switching to other AD treatments or adding to therapy was
comparatively rare during the first year.
 2016 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the
CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
1. Introduction
Type 2 diabetes mellitus (T2DM) is a global public health con-
cern affecting 387 million people world-wide and 52 million
people in Europe. By the year 2035, these numbers are
expected to increase to 592 million and 69 million respec-
tively. In Germany alone, 7.3 million people have T2DM,
equating to one in nine adults affected by the disease [1].
http://dx.doi.org/10.1016/j.diabres.2016.10.025
0168-8227/ 2016 The Authors. Published by Elsevier Ireland Ltd.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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T2DM is a metabolic disorder characterised by hypergly-
caemia and an increased risk of bothmicrovascular complica-
tions (diabetic nephropathy, neuropathy, and retinopathy)
and macrovascular complications (coronary artery disease,
peripheral arterial disease, and stroke). While improved gly-
caemic control can reduce diabetes-related complications,
especially microvascular, almost four in ten patients with
T2DM in Germany fail to reach their target blood glucose
and haemoglobin HbA1c levels [2].
There are today several available therapies for glycaemic
control including insulin, metformin, thiazolidinediones,
sulphonylureas, glucagon-like peptide-1 (GLP-1) receptor ago-
nists, dipeptidyl peptidase-4 (DPP-4) inhibitors and most
recently sodium-glucose co-transporter 2 (SGLT-2) inhibitors.
SGLT-2 is a major transporter of glucose responsible for renal
glucose reabsorption. Dapagliflozin is a highly potent and
selective SGLT2 inhibitor of, with a mechanism of action that
is different from and complementary to the mechanisms of
currently available in other anti diabetic medicine classes. It
improves glycaemic control in patients with T2DM by reduc-
ing renal glucose reabsorption, resulting in the direct,
insulin-independent, elimination of excess glucose by the
kidney. SGLT2 is selectively expressed in the kidney minimis-
ing the risk of off-target (i.e. non-kidney) effects [3].
Dapagliflozin is the first agent of its class to be approved in
the European Union for the treatment of T2DM in adults. It
received marketing approval in November 2012 as a
monotherapy to improve glycaemic control in adults with
T2DM, when adequate glycaemic control was not achieved
through diet and exercise alone and metformin was consid-
ered inappropriate due to intolerance. Dapagliflozin has also
been approved in combination therapy with other glucose-
lowering products including insulin, when these, together
with diet and exercise, do not provide adequate glycaemic
control [3]. In January 2014, a combination product of dapagli-
flozin and metformin received marketing approval for use in
adults with T2DM as an adjunct to diet and exercise to
improve glycaemic control.
In 2013, the German Institute for Quality and Efficiency in
Health Care (IQWiG) carried out a dapagliflozin benefit assess-
ment and reported that the incremental benefit of dapagliflo-
zin over standard therapy could not be demonstrated given
the lack of real-world data from which to form a comparison
[4]. This study aimed to show dapagliflozin use in a real-world
setting by evaluating demographic and clinical characteristics
of dapagliflozin users in comparison to users of other anti-
diabetic (AD) treatments in Germany, and identifying dapagli-
flozin treatment patterns. The study should provide a basis
for understanding how the medical community perceives
dapagliflozin and how it can be used to meet unmet treat-
ment needs.
2. Methods
2.1. Study design and source population
This study adhered to the European Network of Centres for
Pharmacoepidemiology and Pharmacovigilance (ENCePP)
guidance [5]. Datawere obtained from the IMSGermanDisease
Analyzer (DA), an electronic healthcare database with anon-
ymised, individual-level information on more than 13 million
patients and about 77 million prescriptions identified from
over 3000 general practitioner (GP) practices and specialists
[6]. Compared with other patient databases, DA is unique,
being the only database available to include and combine all
information on physicians, patients, diagnoses, and courses
of therapy relevant for the decision-making process. The data
within the DA are obtained directly from GP and specialist
practice computers through standardised interfaces used in
day-to-day practice [7]. The German DA represents 2% of all
practices in Germany and is indicative of the larger general
German population in the health assurance fund with
respect to age, region, prescriptions and diagnoses [6]. The
longitudinal nature of the data provides the ability to track
changes in drug utilisation over time. Becher et al. (2009) found
no indication of lack of representativeness or validity of the DA
database. In principle, the database appears suitable for phar-
macoepidemiological and pharmacoeconomic studies [7].
As with all electronic medical record (EMR) datasets, infor-
mation is limited by the level of detail and quality of informa-
tion recorded by the physician. The low response rate among
physicians is certainly a point of concern andwarrants a thor-
ough investigation of the potential for bias when using the DA
database in a study [7].
The study time period began from the time of first licens-
ing of dapagliflozin in Germany (12 November 2012), until 30
April 2014. The index date was defined as the first-time use
of either dapagliflozin or other AD therapy within the study
time period (new user design). The observation period was
defined as the period between the index date and the end of
data capture (end of the study time period, death or lost to
follow-up). The cohort for this study was defined as patients
who were either: (i) prescribed dapagliflozin or (ii) prescribed
other AD therapies. The primary exposure of interest in this
study was dapagliflozin. Patients prescribed other AD thera-
pies were considered a comparator group. To be included in
the study patients must have had at least one prescription
for dapagliflozin or other AD therapy during the study time
period, at least one recorded diagnosis of T2DM prior to or
on the index date, and a minimum of 6 months of continuous
enrolment within IMS German DA prior to the index prescrip-
tion. Subjects were excluded from the study if they had a
diagnosis of type 1 diabetes mellitus. Covariates measured
at the time of the index date are reported to cover information
on demographic characteristics (age and sex), diabetes his-
tory (duration of T2DM before first AD therapy prescription),
comorbid conditions, concomitant medications, laboratory
parameters and prescriber information.
2.2. Statistical methods
Descriptive analysis was performed using counts and propor-
tions (n, %) for categorical variables; means and medians (SD,
95% CI) were estimated for continuous variables. Variables
were categorised into quartiles as required. Interquartile
range (IQR) and range of data (min, max) were reported. All
statistical analysis was performed using SAS (Cary, North Car-
olina). Graphical display of information was derived from MS
Excel.
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Demographic and clinical characteristics of patients initiat-
ing a new AD therapy (incident users) were reported at the
time of the index date. In particular, patient age, gender, insur-
ance type and residence, diabetes history, comorbid condi-
tions, concomitant medications and laboratory parameters
were reported. Incident users of dapagliflozin and other AD
therapies were analysed separately. Patterns of prescribing
by age and sex were not formally compared between cohorts
due to the heterogeneity of the ‘other AD therapy’ cohort.
The dapagliflozin user cohort was stratified further into
monotherapy users and combination therapy subgroups.
Dapagliflozin prescriber informationwas characterised by pre-
scriber practice type (general practice or diabetologist), age
category of practitioner and number of patients in practice.
To quantify drug utilisation, data on the average daily dose
(ADD) was obtained. ADD of dapagliflozin was defined as the
average dose prescribed over a treatment episode and was
calculated by dividing the total quantity prescribed by the
number of days in the treatment period. Analysis associated
with dose calculations only considered standard dosing avail-
able for dapagliflozin (i.e., 5 mg or 10 mg). Data was also
obtained on subsequent use of insulin or other additional
AD therapy (the proportion of AD therapy users who subse-
quently use insulin vs. those who subsequently use other
additional AD therapies).
Analyses of the treatment patterns of dapagliflozin utilisa-
tion were conducted. Identification of switch in therapy was
defined as the discontinuation of the existing therapy coupled
with a new prescription for an alternative AD therapy. Switch-
ing in therapy from dapagliflozin to other AD therapies as
well as switching in therapy from other AD therapies to dapa-
gliflozin was examined. The presence/absence of a switch,
the time to switch and the drug class involved were reported.
The date of switch was the day immediately preceding the
prescription date of the new product. Add-on therapy for
dapagliflozin users was defined as the addition of a new AD
prescription that overlaps with the existing dapagliflozin pre-
scription, were examined. The number of dapagliflozin users
with add-on therapy, the time to add-on and the drug classes
added were reported.
Dose adjustment for dapagliflozin was defined as the
recorded change in starting dosage (i.e. 5 mg or 10 mg) from
the index treatment. The number of patients affected and
the average time to dose adjustment were reported.
The compliance of dapagliflozin use was examined. Com-
pliance of dapagliflozin was defined as the extent to which a
patient acts in accordance with the prescribed interval and
dose of a dosing regimen [8]. Compliance was quantified by
the medication possession ratio (MPR), which measured the
percentage of time that medication was available for use dur-
ing the period the patient was persistent with dapagliflozin.
MPR was calculated by dividing the number of prescribed
therapy units (i.e., daily doses) for dapagliflozin by the num-
ber of assumed therapy units needed according to the physi-
cian’s individual dose recommendation for the observational
period. A maximum of 100% compliance was assumed for
prescription periods that extended beyond the end of the
study period. MPR was calculated only for patients with more
than one prescription available. Patients with MPR >80% were
considered to be compliant [9]. Average compliance was
reported and sensitivity analysis performed by evaluating
compliances as MPR > 50%, MPR > 60%, MPR > 70% and
MPR > 90%.
3. Results
3.1. Demographic characteristics
A total of 82,868 patients were included in the study; 1405
were identified as dapagliflozin users and 81,463 received
other anti-diabetic medication. Among the dapagliflozin
users 1234 patients used the 10 mg dose (88%) and 171
patients used the 5 mg dose (12%). Overall, 371 patients
(26%) received dapagliflozin monotherapy and 1034 patients
(74%) received dapagliflozin as in combination therapy.
Table 1 outlines the demographic characteristics of dapa-
gliflozin and other AD therapy users. Overall patients on dapa-
gliflozin tended to be younger, with a mean age of 61.3 years
(SD 10.8, range 19.0–92.0) compared to other AD therapy users
[mean age of 68.2 years (SD 12.2, range 18.0–103.0)]. Further-
more, 62.3% (n = 875/1405) of dapagliflozin users were
664 years of age compared to 36.4% (n = 29,687/81,463) of other
AD therapy users. A higher proportion of patients on dapagli-
flozin were male compared to other AD therapy users (59.1%,
n = 830/1405 vs. 53.6%, n = 43,661/81,463 respectively).
Private insurance was utilised by 14.9% (n = 210/1405) of
patients receiving dapagliflozin therapy compared to 5.7%
(n = 4659/81,463) of other AD therapies users. As expected
from the population of the respective regions, 75% of the
dapagliflozin and other AD therapies users resided in West
Germany.
The average duration of diabetes was comparable between
dapagliflozin patients and other AD therapy users (5.7 years,
SD 4.0 vs. 5.5 years, SD 4.5 respectively).
The majority of patients on dapagliflozin monotherapy
were aged between 55 to 64 years (39.6%, n = 147/371), fol-
lowed by those aged 6574 years (22.9%, n = 85/371) and
4554 years (20.8%, n = 77/371). Among dapagliflozin
monotherapy users, men (59.6%, n = 221/371) were more fre-
quently being prescribedwith dapagliflozin than werewomen
(40.4%, n = 150/371). Similar age and gender trends were seen
for the 1034 patients on dapagliflozin combination therapy.
Dapagliflozin users were reported to have higher levels of
HbA1c (8.2% (66 mmol/mol), SD 1.5, N = 902), fasting plasma
glucose (172.7 mg/dl, SD 59.0, N = 677) and glomerular filtra-
tion rate (80.8 ml/min, SD 22.0, N = 174) compared to other
AD therapy users (7.5% (59 mmol/mol), SD 1.4, N = 47,097;
156.9 mg/dl, SD 62.6, N = 38,872 and 74.6 ml/min, SD 25.95,
N = 7997 respectively) (Table 2). There was substantial missing
data for BMI and smoking status; therefore no comparisons
between the two treatment groups was analysed.
3.2. Comorbid conditions and concomitant medications
Comorbid conditions were grouped into three categories:
those indicative of disease progression (retinopathy, diabetic
neuropathy, nephropathy, and diabetes ketoacidosis), those
related to cardiovascular diseases (myocardial infarction,
chronic heart failure, stroke, arrhythmia and heart valve
disorders) and for those associated with hepatic disease and
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hypertension. The incidence of conditions indicative of
diabetes progression was similar for dapagliflozin and other
AD therapy users although dapagliflozin users were slightly
less likely than other AD therapy users to show signs of
nephropathy (15.2%, n = 214/1405 vs. 18.6%, n = 15,191/81,463)
(Table 3). Dapagliflozin users experienced a history of
cardiovascular disease less frequently than other AD therapy
users, in particular in relation to chronic heart failure
(9.7%, n = 136/1405 vs. 15.8%, n = 12,877/81,463), stroke (3.3%,
n = 46/1405 vs. 6.2%, n = 5081/81,463), and arrhythmia (10.7%,
n = 151/1405 vs. 16.7%, n = 13,610/81,463). However, patients
on dapagliflozin suffered more frequently from hepatic
disease than other AD therapy users (19.1%, n = 268/1405 vs.
14.8%, n = 12,060/81,463). A high incidence of hypertension
was seen in all patients regardless of therapy (69.3–75.1%),
however, dapagliflozin monotherapy users showed a slightly
lower risk compared to those on combination therapy
(69.3%, n = 257/371 vs. 74.1%, n = 766/1034) and other AD ther-
apies (75.1%, n = 61,153/81,463). There were no distinct differ-
ences between dapagliflozin monotherapy and combination
therapy users in these respects.
Among the concomitant medications prescribed for dapa-
gliflozin users immediately prior to the index date (during the
6 months before index) (Appendix A), a high proportion of
Table 1 – Demographic characteristics for dapagliflozin (overall, monotherapy, combination therapy) and other AD therapy
users.
Variables Dapagliflozin Other AD therapy
Overall
N = 1405
Monotherapy
N = 371
Combination
N = 1034
Overall
N = 81463
Age, n (%)
18–34 16 (1.1) 6 (1.6) 10 (1.0) 592 (0.7)
35–44 75 (5.3) 19 (5.1) 56 (5.4) 2213 (2.7)
45–54 277 (19.7) 77 (20.8) 200 (19.3) 8746 (10.7)
55–64 507 (36.1) 147 (39.6) 360 (34.8) 18,136 (22.3)
65–74 358 (25.5) 85 (22.9) 273 (26.4) 23,829 (29.3)
75+ 172 (12.2) 37 (10.0) 135 (13.1) 27,947 (34.3)
Mean age, years (SD) 61.3 (10.8) 60.4 (10.5) 61.6 (10.9) 68.2 (12.2)
Gender, n (%)
Male 830 (59.1) 221 (59.6) 609 (58.9) 43,661 (53.6)
Female 575 (40.9) 150 (40.4) 425 (41.1) 37,802 (46.4)
Weight, kg (N, SD) 100.3 99.4 100.6 90.5
(441, 21.7) (106, 18.5) (335, 22.6) (19,126, 20.0)
Insurance type, n (%)
Statutory 1195 (85.1) 309 (83.3) 886 (85.7) 76.804 (94.3)
Private 210 (14.9) 62 (16.7) 148 (14.3) 4659 (5.7)
Residence, n (%)
West Germany 1049 (74.7) 289 (77.9) 760 (73.5) 61,084 (75.0)
East Germany 356 (25.3) 82 (22.1) 274 (26.5) 20,379 (25.0)
Duration of diabetes
Mean, years (SD) 5.7 (4.0) 5.2 (3.9) 5.9 (4.1) 5.5 (4.5)
Table 2 – Laboratory parameters for dapagliflozin (overall, monotherapy, combination therapy) and other AD therapy users.
Variables Dapagliflozin Other AD therapy
Overall Monotherapy Combination Overall
HbA1c, mean% (mmol/mol) (SD, N) 8.2 8.1 8.2 7.5
66 65 66 59
(1.5, 902) (1.6, 233) (1.4, 669) (1.4, 47,097)
Fasting plasma glucose, meanmg/dl (SD, N) 172.7 169.3 173.9 156.9
(59.0, 677) (60.5, 178) (58.5, 499) (62.6, 38,872)
Glomerular filtration rate, mean ml/min (SD, N) 80.8 78.1 81.9 74.6
(22.0, 174) (19.3, 51) (23.0, 123) (26.0, 7997)
Serum creatinine 0.90 0.90 0.90 1.00
mean mg/dL, (SD, N) (0.28, 886) (0.23, 231) (0.29, 655) (0.42, 46,073)
HDL Cholesterol, meanmg/dL (SD, N) 45.9 47.2 45.4 48.8
(12.3, 678) (12.4, 179) (12.2, 499) (14.6, 33,043)
LDL Cholesterol, meanmg/dL (SD, N) 119.5 122.8 118.4 118.2
(39.2, 673) (39.6, 175) (39.0, 498) (39.0, 32,423)
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patients on dapagliflozin were prescribed metformin (67.6%,
n = 950/1405) and dipeptidyl peptidase-4 (DPP-4) inhibitors
(44.9%, n = 631/1405) respectively. Prescriptions for insulin
and analogues were also common (35.9%, n = 505/1405). A
large number of dapagliflozin users (53.2%) were prescribed
an angiotensin converting enzyme inhibitor (ACE-I) and
angiotensin II receptor blocker (ARB).
3.3. Prescription patterns of dapagliflozin
The uptake of dapagliflozin has grown steadily since its
launch in Germany in 2012 (Fig. 1). The greatest increase in
prescription volume was observed between the first and sec-
ond quarter of 2013, with the majority of prescriptions being
made for 10 mg dapagliflozin. Uptake slowed slightly from
the third quarter of 2013 onwards. After a low uptake of
5 mg dapagliflozin, a noticeable increase in prescription vol-
ume was observed, from 74 in the third quarter of 2013 to
171 in the second quarter of 2014.
For most patients, dapagliflozin and other AD therapies
were prescribed by a GP, but a higher proportion of patients
had dapagliflozin prescribed by a specialist diabetologist
(26.3%, n = 369/1405) compared to other AD therapies (18.7%,
n = 15,244/81,463). The age distribution of prescribing practi-
tioners was similar for dapagliflozin and other AD therapy
users, however, it should be noted that in practices with mul-
tiple doctors, only the age group of the lead doctor was given
(Appendix B).
Table 4 outlines the therapy type (monotherapy/combina-
tion) and drug classes used in combination with dapagliflozin
for the 10 mg and 5 mg populations at index date. Only 28.5%
(n = 325/1234) of patients who were using 10 mg dapagliflozin
and 11.1% (n = 19/171) of patients using 5 mg dapagliflozin
had been prescribed this treatment alone at the index date.
Patients using 10 mg dapagliflozin were most commonly pre-
scribed in combination with either biguanide alone (12.3%,
n = 152/1234), biguanide plus a DPP-4 inhibitor (13.2%,
n = 163/1234), or insulin alone (10.1%, n = 125/1234). Of those
Table 3 – Comorbid conditions among dapagliflozin (overall, monotherapy, combination therapy) and other AD therapy users.
Variables Dapagliflozin Other AD therapy
Overall
N = 1405
n (%)
Monotherapy
N = 371
n (%)
Combination
N = 1034
n (%)
Overall
N = 81463
n (%)
Marker of diabetes disease progression and complications
Retinopathy 120 (8.5) 17 (4.6) 103 (10.0) 5620 (6.9)
Diabetic neuropathy 292 (20.8) 66 (17.8) 226 (21.9) 17,322 (21.3)
Nephropathy 214 (15.2) 47 (12.7) 167 (16.2) 15,191 (18.6)
Diabetic ketoacidosis 2 (0.1) 0 (0) 2 (0.2) 164 (0.2)
Cardiovascular disease
Myocardial infarction 47 (3.3) 14 (3.8) 33 (3.2) 3154 (3.9)
Chronic heart failure 136 (9.7) 37 (10.0) 99 (9.6) 12,877 (15.8)
Stroke 46 (3.3) 9 (2.4) 37 (3.6) 5081 (6.2)
Arrhythmia 151 (10.7) 49 (13.2) 102 (9.9) 13,610 (16.7)
Heart valve disorders 36 (2.6) 13 (3.5) 23 (2.2) 3945 (4.8)
Hypertension 1023 (72.8) 257 (69.3) 766 (74.1) 61,153 (75.1)
Other
Hepatic disease 268 (19.1) 66 (17.8) 202 (19.5) 12,060 (14.8)
Fig. 1 – Cumulative prescription pattern of dapagliflozin over time.
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whowere using 5 mg dapagliflozin, combination therapy with
biguanide alone (32.7%, n = 56/171), biguanide plus insulin
(12.9%, n = 22/171) or biguanide plus DPP-4 inhibitor (8.2%,
n = 14/171) were the most common regimens prescribed. A
large proportion of patients who initiated on dapagliflozin
did so in combination with insulin (27.3%, n = 384/1405).
Overall, 62 (4.4%) dapagliflozin patients had their dose
adjusted, with a mean adjusting time of 36 days (SD 33, range
1–219). 12 patients (0.9%) given the 10 mg dapagliflozin formu-
lation had their dose adjusted after a mean period of 61 days
(SD 60, range 1–219) and 50 patients (3.6%) given the 5 mg for-
mulation had their dose adjusted after a mean period of
30 days (SD 16, range 7–106).
At the time of the index prescription, in total, 85.1%
(n = 1196/1405) of users were not switched to dapagliflozin
from a previous therapy but either had no previous AD med-
ication or added dapagliflozin to another AD compound. For
those that were switched to dapagliflozin, the most common
previous therapies were DPP-4 inhibitors (5.4%, n = 76/1405),
insulin (2.5%, n = 35/1405), and GLP-1 inhibitors (2.1%,
n = 30/1405).
During the observation period, only a small proportion of
the total population of dapagliflozin users (6.3%, n = 89/1405)
were switched onto another therapy (after a mean of
134 days, SD 108, range 5–452). Overall, the most common
drug classes that dapagliflozin users switched to were found
to be insulin (30.3%, n = 27/89), DPP-4 inhibitors (15.7%,
n = 14/89), and sulfonylureas (14.6%, n = 13/89) (Appendix C).
Overall, add-on therapy was prescribed for a moderate
number of patients on dapagliflozin during the observation
period (13.4%, n = 188/1405) after a mean of 105 days (SD 91,
range 1–410) (Appendix D).
A high rate (80%) of patient compliance was observed at
the P90% threshold. As per sensitivity analyses, for thresh-
olds of MPRP 70%, MPRP 60% and MPRP 50%, the compli-
ance proportions were 92%, 95% and 97%, respectively.
4. Discussion
Within a German population, patients on dapagliflozin
differed in important characteristics to patients using other
AD medicine. This study shows that patients on dapagliflozin
tended to be younger and a higher proportion were male
(3:2 ratio of male to female). The average duration of
diabetes was comparable between dapagliflozin and other
AD therapy users but patients on dapagliflozin were on aver-
age heavier and had higher levels of HbA1c and fasting
plasma glucose.
The majority of patients on dapagliflozin were aged from
45–74 years with a mean age of around 61 years, whereas
the highest proportion of other AD therapy users were over
75 years. The much lower proportion of dapagliflozin users
over 75 years may be due to prescription guidelines suggest-
ing that initiation of dapagliflozin therapy is not recom-
mended in patients over 75 years due to the limited
therapeutic experience in this age group [3].
Patients on dapagliflozin had less glycaemic control than
patients on other AD therapies. The recommended daily tar-
get for HbA1c levels for people with diabetes is 6.5%
(48 mmol/mol). The recommended level for those at greater
risk of hypoglycaemia is 7.5% (59 mmol/mol) [10–12]. In this
study, dapagliflozin users averaged 8.2% (66 mmol/mol) com-
pared to 6.9% (52 mmol/mol) for other AD therapy users. The
higher HbA1c and fasting plasma glucose levels found in
dapagliflozin users in this study may be a result of the dapa-
gliflozin treatment pathway rather than a consequence of its
use. The preference to use dapagliflozin as a second or third-
line treatment option, generally when other therapies have
not provided adequate glycaemic control, would suggest that
higher HbA1c and fasting plasma glucose levels were evident
prior to initiation of the therapy.
A higher proportion of patients using dapagliflozin had
private insurance and had their therapy prescribed by a spe-
cialist diabetologist compared to other AD therapy users.
Approximately 10% of the German population are privately
insured [13]. Approximately 15% of dapagliflozin users had
private insurance compared to only 6% of other AD therapy
users. This is consistent with a recent study on the treatment
patterns of T2DM patients in Germany, which found those
who were privately insured had a higher probability of being
prescribed newer anti-hyperglycaemic drugs (AHD) than
patients on statutory insurance [13].
Table 4 – Therapy type (monotherapy/combination) and drug classes for dapagliflozin combination therapy users at index
date.
Therapy type Dapagliflozin dose
10mg
(N = 1234)
n (%)
5 mg
(N = 171)
n (%)
Monotherapy dapagliflozin 352 (28.5) 19 (11.1)
Combination therapies 882 (71.5) 152 (88.9)
Dapagliflozin + biguanide + DPP-4 inhibitor 163 (13.2) 14 (8.2)
Dapagliflozin + biguanide 152 (12.3) 56 (32.7)
Dapagliflozin + insulin 125 (10.1) 10 (5.8)
Dapagliflozin + biguanide + insulin 104 (8.4) 22 (12.9)
Dapagliflozin + biguanide + DPP-4 inhibitor + insulin 54 (4.4) 10 (5.8)
Other combination 284 (23.0) 40 (23.4)
Including insulin 49 (4.0) 10 (5.8)
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Patients on dapagliflozin were more likely to be suffering
from comorbid liver disease but less likely to suffer from
comorbid kidney disease than patients on other AD therapies.
The prescription guidelines report that the efficacy of dapagli-
flozin is reduced in patients with renal impairment and sug-
gests that dapagliflozin should not be prescribed for
patients with moderate to severe renal impairment [3]. Our
findings are consistent with these guideline
recommendations.
Patients on dapagliflozin were less likely to experience a
history of cardiovascular (CV) disease, including heart fail-
ure, stroke and arrhythmia, than those on other AD thera-
pies. This would indicate that prescribing of dapagliflozin
was more restrictive in patients with a history of cardiovas-
cular disease. Notably, the recent findings of the EMPA-REG
clinical trial showed a reduction in hospitalization for heart
failure and cardiovascular mortality in patients randomized
to empagliflozin compared to placebo on top of standard of
care [14]. It is yet unclear to what extent these effects are
also present for other SGLT2 inhibitors. A cardiovascular
outcome trial for dapagliflozin (the DECLARE study) is
ongoing.
During the 6 months before the index date a high pro-
portion of patients on dapagliflozin were prescribed met-
formin (a biguanide), especially those initiated on
dapagliflozin combination therapy. Metformin is the most
widely prescribed first-line drug for T2DM in Germany and
accounted for 63% of newly prescribed OADs in 2003 and
more than 80% in 2009 [15]. The high proportion of dapagli-
flozin users who were previously prescribed metformin
reflect these high prescriptions figures. It can be assumed
that in patients previously prescribed metformin, glycaemic
control was inadequate or an intolerance to metformin was
evident, thus necessitating the use of additional treatment.
Studies where dapagliflozin was added onto metformin
therapy show improvements to HbA1c levels and body
weight and validate the use of dapagliflozin as a next line
treatment option [16–19]. Approval in January 2014 of the
combination dapagliflozin/metformin therapy may see a
further increase in metformin users being prescribed this
combination therapy.
A review of treatment guidelines for T2DM suggests that if
metformin is not tolerated or contraindicated then the second
choice of first-line drug therapy is generally monotherapy
with DPP-4 inhibitors, insulin, sulfonylureas/glinides, glucosi-
dase inhibitors or SGLT2 inhibitors [12]. Furthermore, if HbA1c
targets were not reached using metformin monotherapy then
the treatment could be amplifiedwith the addition of a second
antidiabetic drug (combination therapy) or else metformin
could be discontinued and insulin used alone. In this study,
in addition to metformin, prescriptions for DPP-4 inhibitors
and insulin were common in the 6 months prior to dapagliflo-
zin use, again with those initiated on dapagliflozin combina-
tion therapy showing a greater percentage. This study also
found that in the 6 months prior to dapagliflozin treatment
there were no instances of patients who were drug- naı¨ve or
off-therapy, suggesting that dapagliflozin was only prescribed
as a second or third-line treatment option when glycaemic
control was not achieved using alternative therapies.
Patients were not usually switched from other therapies
onto dapagliflozin (Appendix B). Since most patients had pro-
gressive diabetes with a mean average diabetes duration of
5.7 years and were unlikely to be treatment-naı¨ve or off-
therapy, it may be assumed that in the majority of these cases
dapagliflozin was added-on to existing therapy. A moderate
number of patients used dapagliflozin as monotherapy how-
ever, for the vast majority of patients it was prescribed as a
component of combination therapy with either biguanide
alone, biguanide plus a DPP-4 inhibitor, insulin alone, bigua-
nide plus insulin or biguanide plus a DPP-4 inhibitor and insu-
lin. This supports evidence of dapagliflozin use as a second or
third-line treatment option, which is in-line with current
treatment guidelines [12].
Almost a third of patients who initiated on dapagliflozin
did so in combination with insulin (28%, n = 396/1405).
Often over time, therapies that depend on insulin run the
risk of hypoglycaemia, weight gain, decreased insulin sensi-
tivity and eventual loss of effectiveness. This is especially
true in patients with late-stage T2DM who require escalat-
ing insulin doses, often with oral agents such as metformin
to maintain glycaemic control. In these cases dapagliflozin
may be used as a strategy for controlling glycaemia inde-
pendently of insulin. Studies supporting the use of dapagli-
flozin as an add-on to insulin therapy include a 2012
European and North American randomised trial that found
dapagliflozin improved glycaemic control, stabilised insulin
dosing and reduced weight without increasing major hypo-
glycaemic episodes in patients inadequately controlled with
insulin alone or with up to 2 oral antidiabetic drugs [20]. An
extension to this study found this control could be main-
tained for over 104 weeks [21]. A Dutch study into the cost
effectiveness of adding dapagliflozin to insulin for the treat-
ment of T2DM concluded that dapagliflozin in combination
with insulin was a cost-effective treatment option for
patients with T2DM whose insulin treatment regimen did
not provide adequate glycaemic control in a Dutch health-
care setting [22].
There were some limitations to this study. The German
healthcare system is provided through statutory health insur-
ance, whichmeans that GP’s are not involved in the allocation
of healthcare resources. Consequently, right truncation and
early censoring of longitudinal records may be an issue since
patients can readily move between primary care practices
and do not require GP referrals in order to receive specialist
care.
Diabetes therapy may be initiated either in the primary
or secondary care setting. However, given the absence of
linkage information between the German DA and other
healthcare settings, concurrent use of healthcare resources
may lead to a distortion in the utilisation pattern of dia-
betes care.
Continuous enrolment is not explicit in the German DA
but rather inferred from utilisation of services. As a result,
gaps in care may be overlooked and the precise date of
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follow-up cannot be estimated. Censoring due to death can-
not be established due to the absence of linkage with national
mortality data. In addition, measures of liver function or
damage (e.g. ALT, AST) were not reported.
Given the nature of real-world data, there is a possibility of
missing data. However, missing data on diabetes-specific
parameters is less likely. For instance, approximately 70% of
patients are expected to have available information on
HbA1c, although this will be reduced following the start of
diabetes treatment. In this study there was a substantial pro-
portion of missing data for several of the laboratory variables
and for BMI. This limits the interpretation of differences
between starters of dapagliflozin and starters of other AD
agents in this study.
5. Conclusions
Since its launch in Germany in 2012, dapagliflozin uptake has
increased rapidly, mainly as a combination treatment with
biguanide, DPP-4 inhibitors or insulin. In comparison to users
of other AD therapy, patients on dapagliflozin differed in
several demographic as well as health related respects. All
patients on dapagliflozin therapy were prescribed concomi-
tant AD medication prior to initiating dapagliflozin, support-
ing evidence for its use as a second or third-line treatment
option. During a 12 month follow-up, few patients were
switched to other anti-diabetic treatments and few had add-
on therapy after dapagliflozin initiation. Compliance with
treatment was high. These early findings indicate that dapa-
gliflozin is an important complement to traditional anti-
diabetic drugs, including insulin, in the treatment of diabetic
patients.
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Appendix A – Concomitant medications prescribed for dapagliflozin users immediately prior to the index date (overall,
monotherapy, combination therapy).
Concomitant medications Overall
N = 1405
n (%)
Monotherapy
N = 371
n (%)
Combination
N = 1034
n (%)
Diabetic drugs
Metformin 950 (67.6) 200 (53.9) 750 (72.5)
DPP-4 inhibitors 631 (44.9) 138 (37.2) 493 (47.4)
Insulin and analogues 505 (35.9) 82 (22.1) 423 (40.9)
Sulphonylureas 184 (13.1) 32 (8.6) 152 (14.7)
GLP-1 agonists 179 (12.7) 46 (12.4) 133 (12.9)
Thiazolidinediones 24 (1.7) 4 (1.1) 20 (1.9)
Non-diabetic drugs
ACE-I 396 (28.2) 90 (24.3) 306 (29.6)
ARB 380 (27.0) 93 (25.1) 287 (27.8)
ACE-I/ARB 747 (53.2) 174 (46.9) 573 (55.4)
Appendix B – Age category of practitioners prescribing dapagliflozin and other AD therapies.
Age group Dapagliflozin
N = 1405
n (%)
Other AD therapy
N = 81463
n (%)
<40 5 (0.4) 556 (0.7)
41–50 259 (18.4) 17,507 (21.5)
51–60 617 (43.9) 30,825 (37.8)
>60 514 (37.3) 32,575 (40.0)
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Appendix C.
Appendix D.
Appendix E. Supplementary data
Supplementary data associated with this article can be found,
in the online version, at http://dx.doi.org/10.1016/j.diabres.
2016.10.025.
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